MWN 109
Alternative Names: MWN-109Latest Information Update: 20 Feb 2026
At a glance
- Originator Shanghai Minwei Biotechnology
- Class Antihyperglycaemics; Fatty acids; Hepatoprotectants; Obesity therapies; Peptides
- Mechanism of Action Gastric inhibitory polypeptide receptor modulators; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity
- Phase I Type 2 diabetes mellitus
- Preclinical Non-alcoholic steatohepatitis
Most Recent Events
- 20 Jan 2026 Shanghai Minwei Biotechnology initiates enrolment in a phase II trial for Obesity in China (PO, Tablet) (CTR20260203)
- 08 Dec 2025 Shanghai Minwei Biotechnology initiates enrolment in a phase II trial for Obesity in China (PO, Tablet) (CTR20254820)
- 04 Dec 2025 Shanghai Minwei Biotechnology initiates enrolment in a phase II trial for Obesity in China (SC, Injection) (CTR20254812)